Espondiloartritis. Espondilitis anquilosante

  1. Bohórquez Heras, C.
  2. Movasat Hadjkan, A.
  3. Turrión Nieves, A.
  4. Pérez, A.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2017

Issue Title: Enfermedades del sistema inmune y reumatológicas (III) Espondiloartritis. Manifestaciones cutáneas de las enfermedades reumatológicas

Series: 12

Issue: 26

Pages: 1485-1497

Type: Article

DOI: 10.1016/J.MED.2017.01.010 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Introduction Spondyloarthritis (Spa) is the term used to describe patients with similar clinical features. There are ankylosing spondylitis, non-radiographic axial SpA (nr-axSpA), peripheral SpA, psoriatic arthritis, reactive arthritis and arthritis associated with gastrointestinal disease. Pathogenesis and clinical manifestations In the pathogenesis of spondyloarthritis are involved gut microbiome, HLAB27 and the axis interleukin 23-interleukin 17. Patients with Spa have usually chronic inflammatory back pain, oligoarthritis in the lower extremities, dactylitis and enthesitis. Uveitis is the most frequent non-musculoskeletal disease. Classification criteria There are new classification criteria developed by the Assessment of Spondiloarthritis International Society (ASSAS). It allows us to make a diagnosis and early treatment of these patients, thus improving the quality of life, the morning stiffness and pain. Treatment The treatment should be phased, starting with nonsteroidal anti-inflammatories. According to the response, and the involvement of the patient, disease modifying drugs, infiltrations articular and biological agents may be used. Non-pharmacological treatment with physiotherapy and the abandonment of the smoking habit should be recommended in all patients.

Bibliographic References

  • Espoguia: Sociedad Española de Reumatología. Grupo de trabajo ESPOGUIA. Guía de práctica clínica sobre el manejo de los pacientes con espondiloartritis. Madrid: Sociedad Española de Reumatología; 2009.
  • Muñoz-Fernández S, de Miguel E, Cobo-Ibáñez T, Carmona L, Steiner M, Descalzo MA, et al. Early spondyloarthritis: results from the pilot registry ESPIDEP. Clin Exp Rheumatol. 2010;28(4):498-503.
  • Mercieca C, Landewé R, Borg A. Spondylarthropathies: pathogenesis and clinical features. En: EULAR text book on Rheumatic Diseases. 2014.
  • Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human mi-crobiome. Nutr Rev. 2012;70Suppl1:S38.
  • Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, Lories RJ, Baeten DL. Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol. 2015;67:2813.
  • Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multipa-rametric predictive model. Ann Rheum Dis. 2013;72:414-7.
  • Cypers H, Van Praet L, Varkas G, Elewaut D. Relevance of the gut/joint axis for the management of spondyloarthritis in daily clinical practice. Curr Opin Rheumatol. 2014;26(4):371-6.
  • Appel H, Maier R, Bleil J, Hempfing A, Loddenkemper C, Schlichting U, et al. In situ analysis of interleukin-23-and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. Arthritis Rheum. 2013;65:1522-9.
  • Sonnenberg GF, Artis D. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity. 2012;37:601.
  • Reveille JD, Maganti RM. Subtypes of HLA-B27: history and implications in the pathogenesis of ankylosing spondylitis. Adv Exp Med Biol. 2009;649:159-76.
  • Kenna TJ, Robinson PC, Haroon N. Endoplasmic reticulum aminopeptidases in the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford). 2015;54:1549.
  • Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, et al. New criteria for inflammatory back pain in pa-tients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784-8.
  • Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:65.
  • Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009; 68Suppl 2:ii1.
  • Narváez JA, Hernández-GañánJ, Isern J, Sánchez-Fernández JJ. Enfermedades reumatológicas en la columna vertebral: diagnóstico radiológico. Radiología. 2016;58:35-49.
  • Mandl P, Navarro-Compán V, Terslev L, Brandt J, Braun J, Burgos-Vargas R. European League Against Rheuma- tism (EU-LAR). EULAR recommendations for the use of imaging in the diag-nosis and management of spondyloarthritis in clinical practice. Ann Rheum Dis. 2015;74:1327-39.
  • Naredo E, Iagnocco A. One year in review: ultrasound in arthritis. Clin Exp Rheumatol. 2016;34(1):1-10.
  • De Miguel E, Cobo T, Muñóz-Fernández S, Naredo E, Uson J, Acebes JC, et al. Validity of enthesis ultrasound assessment in spondylarthropathy. Ann Rheum Dis. 2009;68:169-74.
  • Rudwaleit AG, Jurik K-GA, Hermann R, Landewe D, van der Heijde X. Baraliakos defining active sacroileitis on magnetic reso-nance imaging (MRI) for classification of axial spondyloarthritis: A consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis. 2009;68:1520-7.
  • Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361-8.
  • Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J. The development of assessment of spondyloarthritis international society (asas) classification criteria for axial spon-dyloarthritis (part ii): validation and final selection. Ann Rheum Dis. 2009;68(6):777-83.
  • Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Braun J. New ASAS classification criteria for peripheral spon-dyloarthritis. Ann Rheum Dis. 2009;68Suppl3:127.
  • Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994; 21(12):2286-91.
  • Calin A, Jones SD, Garrett SL, Kennedy LG. Bath ankylosing spondylitis functional index. Br J Rheumatol. 1995;34(8):793-4.
  • Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol. 1994;21(9):1694-8.
  • Muñoz-Villanueva MC, Muñoz-Gomariz E, Escudero Contreras A, Pérez-Guijo V, Collantes-Estevez E. Biological and clinical markers of disease activity in ankylosing spondylitis. J Rheumatol. 2003;30(12): 2729-32.
  • Creemers MC, Franssen MJ, van’t Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis. 2005;64(1): 127-9.
  • MacKay K, Mack C, Brophy S, Calin A. The Bath Ankylosing Spondylitis Radiology Index (BASRI): a new, validated approach to disease assessment. Arthritis Rheum. 1998;41(12):2263-70.
  • Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L Non steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev 2015;CD010952.
  • Chen J, Liu C. Sulfasalazina para la espondilitis anquilosante.
  • Poddubnyy D, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, et al. Baseline radiographic damage, elevated acute phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-98
  • Van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J.; Assessment of SpondyloArthritis international Society (ASAS). AS-DAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(12):1811-8.
  • Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitisAnn Rheum Dis. 2006;65(3):316-20.
  • Maneiro JR, Souto A, Salgado E, Mera A, Gómez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 201518;1(1):e000017.